# US 11,078,253 B2 · Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,078,253 B2 - Document ID: US11078253B2 - Status: Granted - Kind: B2 - Application number: 17/117,188 - Filed: 2020-12-10 - Published: 2021-04-08 - Granted: 2021-08-03 - Earliest claimed: 2017-01-27 - Assignees: Immatics Biotechnologies GmbH - Applicants: Immatics Biotechnologies GmbH - Inventors: Heiko Schuster; Janet Peper; Kevin Roehle; Philipp Wagner; Hans-Georg Rammensee - Web page: https://patentgrep.com/patent/US11078253B2 ## CPC - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - A61K 39/0011: {Cancer antigens} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor} - A61P 35/00: Antineoplastic agents - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - C07K 16/2818: {against CD28 or CD152} - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 2039/892: {Reproductive system [uterus, ovaries, cervix, testes]} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C12Q 2600/156: Polymorphic or mutational markers - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY ## Abstract The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. ## Claims ### Claim 1 A method of killing target cells in a patient who has cancer, comprising administering to the patient an effective number of activated T cells that selectively recognize a cancer cell, which presents a peptide consisting of the amino acid sequence of APRPASSL (SEQ ID NO: 129), wherein said cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, esophageal cancer, small cell lung cancer, and uterine and endometrial cancer. ### Claim 2 (depends on 1) The method of claim 1, wherein the T cells are autologous to the patient. ### Claim 3 (depends on 1) The method of claim 1, wherein the T cells are obtained from a healthy donor. ### Claim 4 (depends on 1) The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. ### Claim 5 (depends on 1) The method of claim 1, further comprising administering to the patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 6 (depends on 1) The method of claim 1, wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell. ### Claim 7 (depends on 1) The method of claim 1, wherein the cancer is breast cancer. ### Claim 8 (depends on 1) The method of claim 1, wherein the cancer is colorectal cancer. ### Claim 9 (depends on 1) The method of claim 1, wherein the cancer is non-small cell lung cancer. ### Claim 10 (depends on 1) The method of claim 1, wherein the cancer is esophageal cancer. ### Claim 11 (depends on 1) The method of claim 1, wherein the cancer is small cell lung cancer. ### Claim 12 (depends on 1) The method of claim 1, wherein the cancer is uterine and endometrial cancer. ### Claim 13 A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient an effective number of activated T cells that selectively recognize a cancer cell, which presents a peptide consisting of the amino acid sequence of APRPASSL (SEQ ID NO: 129), wherein said cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, esophageal cancer, small cell lung cancer, and uterine and endometrial cancer. ### Claim 14 (depends on 13) The method of claim 13, wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell. ### Claim 15 (depends on 13) The method of claim 13, wherein the cancer is breast cancer. ### Claim 16 (depends on 13) The method of claim 13, wherein the cancer is colorectal cancer. ### Claim 17 (depends on 13) The method of claim 13, wherein the cancer is non-small cell lung cancer. ### Claim 18 (depends on 13) The method of claim 13, wherein the cancer is esophageal cancer. ### Claim 19 (depends on 13) The method of claim 13, wherein the cancer is small cell lung cancer. ### Claim 20 (depends on 13) The method of claim 13, wherein the cancer is uterine and endometrial cancer.